Compare Gilead Sciences, Inc. (GILD) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nucor Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while Nucor Corporation trades at $236.94 (market cap $53.94B). The key difference: Gilead Sciences, Inc. is far larger — about 3× Nucor Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NUE | |
|---|---|---|
Market Cap | $163.51B | $53.94B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $266.35 |
52-Week Low | $108.22 | $131.78 |
Enterprise Value | $178.05B | $58.59B |
Dividend Yield | 2.49% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Nucor (NUE) trades at $234.16, up 0.5% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company maintains a solid balance sheet with a 53-year dividend growth streak. Revenue trends show recovery from 2024 lows, supported by higher steel prices and expansion projects.
Outlook remains positive with a consensus price target of $262.89, though risks include cyclical demand and margin pressures. The stock offers value with a P/E of 23.5 and robust cash flow, but investors should monitor Q2 2026 earnings due soon for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
